Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14516803 | 0.98 | ACHE (0.54) | ACHENPSR1MEN1KMT2AGAA | |
| SCHEMBL21544553 | 0.93 | — | — | |
| SCHEMBL575919 | 0.80 | ACHE (0.50) | ACHENPSR1MEN1KMT2AGAA | |
| SCHEMBL585584 | 0.80 | ACHE (0.61) | ACHENPSR1MEN1KMT2AGAA | |
| SCHEMBL586791 | 0.80 | ACHE (0.61) | ACHENPSR1MEN1KMT2AGAA | |
| SCHEMBL576272 | 0.80 | ACHE (0.50) | ACHENPSR1MEN1KMT2AGAA | |
| SCHEMBL2488188 | 0.77 | ACHE (0.48) | ACHENPSR1MEN1KMT2AGAA | |
| SCHEMBL575719 | 0.77 | ACHE (0.46) | ACHENPSR1MEN1KMT2AGAA | |
| SCHEMBL575222 | 0.77 | ACHE (0.58) | ACHENPSR1MEN1KMT2AGAA | |
| SCHEMBL575885 | 0.77 | ACHE (0.46) | ACHENPSR1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186608-A1 | NANODIAMONDS AS DELIVERY PLATFORM FOR OXIME ANTIDOTES TO CENTRAL NERVOUS SYSTEM IN ORGANOPHOSPHATE POISONING | TALLINN UNIVERSITY OF TECHNOLOGY (EE) | 2025-06-12 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| US-20250114653-A1 | COMPOSITIONS, METHODS, AND ARTICLES COMPRISING COCAINE ESTERASE FOR DETOXIFYING AN ORGANOPHOSPHATE-BASED AGENT | FOUR WINDS BIOTHERAPEUTICS, INC. | 2025-04-10 | — | — | US | claimed |
| US-20250042934-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS, INC. | 2025-02-06 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2024259220-A1 | PON3 AND EVOLVED PON1 FUSION POLYPEPTIDES | THERIPION, INC. (US) | 2024-12-19 | — | — | WO | claimed |
| EP-4373927-A2 | COMPOSITIONS, METHODS, AND ARTICLES COMPRISING COCAINE ESTERASE FOR DETOXIFYING AN ORGANOPHOSPHATE-BASED AGENT | Four Winds Biotherapeutics, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| US-20240027346-A1 | DETECTION METHOD | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-25 | — | — | US | claimed |
| EP-4294827-A1 | PARAOXONASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS | Theripion, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| EP-4247823-A1 | DETECTION METHOD | The University of Queensland (AU) | 2023-09-27 | — | — | EP | claimed |
| US-20060192098-A1 | Sampling swab | SMITHS DETECTION INC. | 2006-08-31 | — | — | US | claimed |
| WO-2006081345-A1 | CHROMOPHORE AND POLYMER CAPABLE OF DETECTING THE PRESENCE OF VARIOUS NEUROTOXINS AND METHOD OF USE | NORTH DAKOTA STATE UNIVERSITY (US) | 2006-08-03 | — | — | WO | claimed |
| US-20050288616-A1 | Sampling swab | SMITHS DETECTION, INC. | 2005-12-29 | — | — | US | claimed |
| EP-1551927-A1 | BIOLOGICAL ACTIVE COATING COMPONENTS, COATINGS, AND COATED SURFACES | McDaniel, Steven C. (US) | 2005-07-13 | — | — | EP | claimed |
| WO-2004112482-A2 | BIOLOGICAL ACTIVE COATING COMPONENTS, COATINGS, AND COATED SURFACES | MCDANIEL STEVEN C (US) | 2004-12-29 | — | — | WO | claimed |
| US-6787680-B2 | Wound dressing impervious to chemical and biological agents | McGowan, Jeremy D. | 2004-09-07 | — | — | US | claimed |
| US-20040109853-A1 | Detoxification surfaces using phosphoric triester hydrolases | REACTIVE SURFACES, LTD. | 2004-06-10 | — | — | US | claimed |
| US-20030163074-A1 | Wound dressing impervious to chemical and biological agents | MCGOWAN JEREMY (US) | 2003-08-28 | — | — | US | claimed |
| US-5935862-A | DETECTING PRESENCE OF CHEMICAL WARFARE AGENTS BY APPLYING LIQUID SAMPLE TO CHROMATOGRAPHIC ADSORBANT MATERIAL AND DETECTOR AGENT USING MICROCAPILLARY TUBE, FORMING CHROMOGENIC INDICATOR; PORTABLE, SENSITIVE, ACCURATE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1999-08-10 | — | — | US | claimed |
| US-5430228-A | Ozone methods for the destruction of chemical weapons | HUGHES AIRCRAFT COMPANY (US) | 1995-07-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240027346-A1 | DETECTION METHOD | NCS1, NGF, ACHE | ACHE 3/4885NPSR1 894/4885MEN1 1127/4885 |
| US-20250042934-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, ADRA2B, ADRA1B | ACHE 188/4885NPSR1 75/4885MEN1 1705/4885 |
| US-20250186608-A1 | NANODIAMONDS AS DELIVERY PLATFORM FOR OXIME ANTIDOTES TO CENTRAL NERVOUS SYSTEM IN ORGANOPHOSPHATE POISONING | ACHE, BCHE, DDT | ACHE 1/4885NPSR1 1560/4885MEN1 4199/4885 |
| US-20250114653-A1 | COMPOSITIONS, METHODS, AND ARTICLES COMPRISING COCAINE ESTERASE FOR DETOXIFYING AN ORGANOPHOSPHATE-BASED AGENT | CES2, BCHE, ACHE | ACHE 3/4885NPSR1 2293/4885MEN1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.